As an active immunotherapy, Mw can activate CD8+ T cells to target DSC3 expressing cancer cells while downregulating tumor induced immunosuppression by decreasing intratumoral FoxP3 and PD-1 expressing immune cells; thus, Mw can be effectively used for management of cancers expressing DSC3. The gene discussed is FOXP3; the disease is neoplasm.